{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026262","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2026-08-06T20:09:28+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:12:22.222400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance","bullets":["Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.","Net loss narrowed to $3.2M ($0.07/sh) from $3.8M ($0.09/sh); Adjusted EBITDA loss improved to $0.7M from $2.0M.","Reaffirmed FY2026 revenue guidance $59.0M-$60.0M; Surgical Aesthetics expected $54.0M-$55.0M.","Limited commercial launch of power liposuction handpiece for AYON platform began in June 2026 after FDA clearance.","Cash and equivalents $27.6M; management expects to yield cash through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026262","json":"https://secwatch.observer/filing/0001437749-26-026262.json","markdown":"https://secwatch.observer/filing/0001437749-26-026262.md","text":"https://secwatch.observer/filing/0001437749-26-026262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/0001437749-26-026262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/apyx20260602_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:12:22.222400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}